Methergin (Methylergometrine Maleate)

Methylergometrine maleate works by partially stimulating serotonin 5‑HT2 receptors and alpha‑adrenergic receptors on uterine smooth‑muscle cells. This dual activation raises intracellular calcium levels, producing a sustained contraction of the myometrium that compresses uterine vessels and limits hemorrhage.

The specific dose of Methergin is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. It is administered by intramuscular or intravenous injection under medical supervision, and dosing guidelines are provided in the product’s prescribing information.

Methergin is intended for use in pregnant women during the peripartum period to manage uterine bleeding. Its safety profile in pregnancy and lactation is not fully classified; therefore, it should only be used when clearly indicated and under the direction of a qualified obstetrician.

To order Methergin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

The primary alternative to Methergin is oxytocin, another uterotonic. Oxytocin acts mainly on oxytocin receptors, producing rapid but shorter‑lasting uterine contractions. Methylergometrine provides a longer duration of action through serotonergic and adrenergic pathways, which can be advantageous when sustained tone is needed, though it carries a higher risk of vasospasm and hypertension.

Methergin should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and avoid shaking the vial. Prior to use, allow the solution to reach room temperature if required, and inspect for any particulate matter before administration.

Methergin is administered by a healthcare professional as a sterile injection, either intramuscularly or intravenously, depending on the clinical situation. The injection is typically given slowly to reduce the risk of cardiovascular side effects, and the patient is monitored closely during and after administration.

Serious adverse events include severe vasospasm leading to peripheral or coronary artery constriction, marked hypertension, myocardial ischemia, pulmonary edema, and anaphylactic reactions. Prompt recognition of chest pain, sudden high blood pressure, or respiratory distress is essential, and immediate medical intervention should be initiated.

Methergin is contraindicated in patients with known hypersensitivity to ergot alkaloids, uncontrolled hypertension, severe coronary artery disease, or a history of vasospastic disorders. Caution is also advised in individuals receiving other potent vasoconstrictors or those with significant renal impairment, where dose adjustment may be required.